Morris, Luc G. T.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 4,071

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 3,380

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,401

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature

Glioma Diagnosis and TreatmentEpigenetics and DNA Methylation

Cited by 1,974

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,142

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell

Advanced Breast Cancer TherapiesHippo pathway signaling and YAP/TAZ

Cited by 508

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2021) · Nature Communications

Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis

Cited by 441

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer

Cancer Immunotherapy and BiomarkersBRCA gene mutations in cancer

Cited by 219

Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison

Ahn, J., Yang, L., Paster, B. J., Ganly, I., Morris, L., Pei, Z., & Hayes, R. B. (2011) · PLoS ONE

Oral microbiology and periodontitis researchGut microbiota and health

Cited by 183

Acoustic rhinometry predicts tolerance of nasal continuous positive airway pressure: a pilot study

Morris, L. G., Setlur, J., Burschtin, O. E., Steward, D. L., Jacobs, J. B., & Lee, K. C. (2006) · American Journal of Rhinology

Obstructive Sleep Apnea ResearchNasal Surgery and Airway Studies

Cited by 64